

PASSING OF GENMAB A/S' ANNUAL GENERAL MEETING

Summary: At Genmab A/S' Annual General Meeting held today on April 15, 2009 the Annual Report for 2008 was approved, discharge was given to the Board of Directors and the Management and the year's loss was carried forward. One member of the Board of Directors retired and another member was re-elected. PricewaterhouseCoopers was re-elected as auditor of the Company. The proposals from the Board of Directors to change the Articles of Association were adopted.

Copenhagen, Denmark; April 15, 2009 – Genmab A/S (OMX: GEN) held its Annual General Meeting, today April 15, 2009 at 2:00 pm at Radisson SAS Scandinavia Hotel, Amager Boulevard 70, 2300 Copenhagen S, Denmark.

At the meeting Chairman of the Board Dr. Michael B. Widmer gave – on behalf of the Board – a report on the Company's activities during the past year. Chief Executive Officer and member of the Board, Lisa N. Drakeman presented plans for the year ahead, and Chief Financial Officer David Eatwell presented the Annual Report for 2008 endorsed by the auditors. The report was approved and discharge was given to the Board and the Management.

It was decided that the year's loss of DKK 772 million be carried forward by transfer to accumulated deficit, as stated in the Annual Report.

Dr. Ernst Schweizer retired from the Board and Hans Henrik Munch-Jensen was re-elected to the Board for a three year period.

PricewaterhouseCoopers Statsautoriseret Revisionsaktieselskab A/S was reelected as the Company's auditor.

The General Meeting adopted the proposals from the Board to change the Company's Articles of Association, as follows:

- The proposal to remove Schedule B due to all warrants granted under the Company's warrant programmes from 1999–2003 pursuant to Article 5 of the Articles of Association have been exercised or have lapsed as non exercised.
- The proposal to amend Article 6 so that VP Investor Services A/S' address "Helgeshøj Allé 61, P.O. Box 20, 2630 Taastrup" is replaced with "Weidekampsgade 14, 2300 Copenhagen S".

PASSING OF GENMAB A/S' ANNUAL GENERAL MEETING

- The proposal to amend Article 8 so that the name “OMX The Nordic Exchange Copenhagen” is replaced with “NASDAQ OMX Copenhagen”.

About Genmab A/S

Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer. Genmab's world class discovery, development and manufacturing teams are using cutting-edge technology to create and develop products to address unmet medical needs. Our primary goal is to improve the lives of patients who are in urgent need of new treatment options. For more information on Genmab's products and technology, visit www.genmab.com.

This Stock Exchange Release contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the section “Risk Management” in Genmab's Annual Report, which is available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Stock Exchange Release nor to confirm such statements in relation to actual results, unless required by law.

Genmab[®]; the Y-shaped Genmab logo[®]; HuMax[®]; HuMax-CD20[®]; HuMax-EGFr[™]; HuMax-IL8[™]; HuMax-TAC[™]; HuMax-HepC[™]; HuMax-CD38[™]; HuMax-CD32b[™]; HuMax-TF[™]; HuMax-Her2[™]; HuMax-VEGF[™] and UniBody[®] are all trademarks of Genmab A/S. Arzerra[™] is a trademark of GlaxoSmithKline.

Contact: Helle Husted, Vice President, Investor Relations
T: +45 33 44 77 30; M: +45 25 27 47 13; E: h.husted@genmab.com

###